Three of the top 20 highest-valued Philadelphia area startups are Penn spinouts
The Philadelphia Business Journal recently ranked the 20 highest-valued startups in Greater Philadelphia.
PCI and JPOD included in the Technical.ly Philly list of resources to boost Philly health startups
A list of Penn programs, partners and friends that work together to support new health startups in the Philadelphia region.
Former I-Corps company making breast pumping easier for moms
Adriana Vazquez spent years perfecting her breast pumping bra for company Lilu.
Interius BioTherapeutics Moves to Pennovation Lab
In October 2021, Interius BioTherapeutics (“Interius”) signed a 17,743 SF lease advancing cell and gene therapy research at the Pennovation Works innovation ecosystem.
Luxturna inventor Jean Bennett starts a new gene therapy company to tackle rare diseases left behind by pharma, VCs
Jean Bennett, who designed and co-developed Luxturna, approved in 2018 for a rare form of blindness, had kept building new gene therapies for eye diseases at her University of Pennsylvania lab.
Webinar Recording: Latest Trends in Life Science Investing
PCI hosted a webinar on Septembe 13, 2021 focused on the latest trends in the venture capital landscape. The speaker was Barbara Schilberg, Managing Director and Chief Executive Officer of BioAdvance.
BioNTech reports promising data on mRNA cocktail in mouse models of colon cancer and melanoma
A BioNTech-led team designed a cocktail of mRNAs that instruct cells to produce four cancer-fighting molecules.
iECURE emerges with $50M to search for ‘holy grail’ and ‘untapped frontier’ of gene editing
The biotech will use the funds for a slate of gene insertion programs for liver disorders out of the lab of gene therapy pioneer Jim Wilson, M.D., Ph.D. at Penn.
Philly life science firms raised more than $777M in the first half of 2021 alone
According to a new CBRE report, life science firms are on pace for a record year. Plus, a look at lab space occupancy.
One of Tachi’s newly born legacy biotechs raises $135M and enlists an A-list board to advance late-stage vaccine
Tachi Yamada's biotechs are continuing to make news.